Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Limited
Femme et Homme Max 99 ans
Merck Sharp & Dohme Limited
MAJ Il y a 4 ans
A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
To determine the anti-tumor effectiveness of oral suberoylanilide hydroxamic acid (SAHA) as measured by overall objective response rate (ORR) in patients with relapsed DLBCL (de novo or transformed).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Limited
MAJ Il y a 4 ans
A Multicenter, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo and Zolmitriptan for the Acute Treatment of Migraine With or Without Aura
To evaluate the efficacy and safety of MK-0974 compared to placebo and zolmitriptan in the treatment of acute migraine.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Limited
MAJ Il y a 4 ans
A randomized, double-blind, placebo-controlled study to evaluate the persistence of the effect of oral monthly ibandronate on bone resorption in postmenopausal women with osteoporosis
In postmenopausal women with osteoporosis, to evaluate and compare with placebo the persistence of the effect of oral monthly ibandronate, 100 mg and 150 mg, on percent change from baseline in the bio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Limited
MAJ Il y a 4 ans
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin
To demonstrate the efficacy of MK-0524 to protect against niacin-induced flushing in patients who resume therapy with either MK-0524A 2g or ER-niacin 2g after a 5 day drug holiday from a stable dose o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations